23Andme Net Worth (Updated 2025).
23andMe was founded in 2006 by Anne Wojcicki, a former Wall Street securities analyst, and Linda Avey, a biotech industry veteran. The company was born out of a desire to make genetic information accessible and useful to individuals, marking the beginning of a new era in personal genomics.
23andMe gained widespread attention in 2007 when it launched its first service, offering customers the opportunity to have their entire genome sequenced for a fee of $999. This was a significant departure from traditional genetic testing services, which typically focused on specific genes or conditions. The company’s innovative approach and competitive pricing quickly attracted media attention and a substantial customer base, catapulting 23andMe to fame in the burgeoning field of direct-to-consumer genetic testing.
**23andMe’s Current Net Worth (2025)**
As of 2025, 23andMe’s current net worth is estimated to be around $3.5 billion, according to the latest available information. This significant valuation reflects the company’s growth and success in the direct-to-consumer genetic testing market.
**Career**
Founded in 2006 by Linda Avey, Paul Cusenza, and Anne Wojcicki, 23andMe pioneered direct-to-consumer genetic testing. Wojcicki, a biologist and entrepreneur, serves as the CEO, driving the company’s mission to help people access, understand, and benefit from their genetic information.
**Other Ventures**
In addition to its core genetic testing services, 23andMe has ventured into pharmaceutical research. The company has partnerships with several pharmaceutical giants, such as GlaxoSmithKline and Pfizer, to develop new drugs based on genetic insights from its customer database.
**Assets**
23andMe’s primary asset is its vast customer database, which contains genetic information from over 10 million customers worldwide. The company also owns a state-of-the-art DNA testing laboratory in San Francisco, California. Additionally, 23andMe holds a robust intellectual property portfolio, including numerous patents related to genetic testing and analysis.
**Annual Income**
In 2021, 23andMe’s annual revenue was reported to be around $500 million. The company’s revenue primarily comes from its direct-to-consumer genetic testing services, with a smaller portion from its partnerships with pharmaceutical companies for drug development.
Frequently Asked Questions about 23Andme
**Frequently Asked Questions about 23AndMe Net Worth**
1. What is 23AndMe?
23AndMe is a direct-to-consumer genetic testing company, founded in 2006 by Anne Wojcicki, Linda Avey, and Paul Cusenza. It offers DNA testing services for health, ancestry, and traits, providing individuals with insights into their genetic information.
2. How does 23AndMe work?
23AndMe uses a saliva sample provided by the customer to extract DNA. This DNA is then analyzed using a genotyping platform, which reads specific locations on the genome to provide information about the customer’s ancestry, health, and traits.
3. What services does 23AndMe offer?
23AndMe offers several services, including Ancestry Service, Health + Ancestry Service, and a range of individual health reports. Their Ancestry Service provides information about a customer’s genetic ancestry and relatives, while their Health + Ancestry Service includes all ancestry features plus health reports on topics like genetic health risks, carrier status, and traits.
4. Is 23AndMe accurate?
23AndMe’s accuracy is generally considered high, with a reported accuracy of over 99% for their ancestry reports. However, it’s important to note that genetic testing has limitations, and results should be interpreted with caution. It’s always a good idea to consult with a healthcare provider when discussing genetic health information.
5. How much does 23AndMe cost?
The cost of 23AndMe’s services varies. As of now, their Ancestry Service is $99, and their Health + Ancestry Service is $199. They also offer individual health reports for $129 each.
6. Is 23AndMe FDA-approved?
Yes, 23AndMe is the first and only direct-to-consumer genetic testing company to receive FDA authorization for its health reports. They have received authorization for over 30 health reports, including those related to genetic health risks, carrier status, and traits.
7. How does 23AndMe protect customer data?
23AndMe has robust data protection measures in place, including encryption, secure data storage, and strict access controls. They also offer customers the option to opt out of research and to delete their data at any time. However, it’s important to note that genetic information can be sensitive, and there are inherent risks associated with sharing this type of data.
8. Can 23AndMe results be used by insurance companies?
In the United States, the Genetic Information Nondiscrimination Act (GINA) prohibits health insurers from using genetic information to deny coverage or charge higher premiums. However, this protection does not apply to life, disability, or long-term care insurance. It’s always a good idea to consult with a legal or insurance professional when discussing the implications of genetic testing results.
9. What is 23AndMe’s net worth?
As of the latest estimates, 23AndMe’s net worth is approximately $3 billion.
10. What is 23AndMe’s business model?
23AndMe generates revenue through the sale of its genetic testing services. They also have a research division, 23andMe Research, which collaborates with academic institutions and pharmaceutical companies to conduct genetic research. Additionally, they have a drug discovery division, 23andMe Therapeutics, which is focused on developing new medicines based on genetic insights.
